fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

CHMP recommends Livogiva, a teriparatide biosimilar for the treatment of osteoporosis. Alvogen

Written by | 28 Jun 2020 | Pharmacy

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Livogiva ( formerly PF 708 and Bonsity in the US), intended for the treatment of osteoporosis. The applicant for this medicinal product is Theramex Ireland Limited. Alvogen has exclusive rights to commercialize and manufacture PF 708 in the EU.

Livogiva will be available as a solution for injection (20 micrograms/80 microlitres). The active substance of Livogiva is teriparatide, the active aminoterminal fragment of human parathyroid hormone . It acts via the receptor for parathyroid hormone and has an anabolic effect on bone. Livogiva is a biosimilar medicinal product. It is highly similar to the reference product Forsteo (teriparatide), which was authorised in the EU on 10 June 2003. Data show that Livogiva has comparable quality, safety and efficacy to Forsteo.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.